Aysha Al Moosa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Aysha Al Moosa has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Cathal O. Connor
Dermatology, South Infirmary Victoria University Hospital , Cork
2 shared publications - Michelle Murphy
Dermatology South Infirmary Victoria University Hospital Cork Ireland
2 shared publications - Abdu-Alaziz Khaskieh
School of Medicine, Royal College of Surgeons in Ireland, Medical University of Bahrain (RCSI-Bahrain), Busaiteen P.O. Box 15503, Bahrain
1 shared publication - Abdullah Hussain
School of Medicine, Royal College of Surgeons in Ireland, Medical University of Bahrain (RCSI-Bahrain), Busaiteen P.O. Box 15503, Bahrain
1 shared publication - Ahmed Abdulkarim Y. Alaysereen
School of Medicine, Royal College of Surgeons in Ireland, Medical University of Bahrain (RCSI-Bahrain), Busaiteen P.O. Box 15503, Bahrain
1 shared publication - Ali Husain Ali Zayer
School of Medicine, Royal College of Surgeons in Ireland, Medical University of Bahrain (RCSI-Bahrain), Busaiteen P.O. Box 15503, Bahrain
1 shared publication
Latest Publications
- Open Access
Topical Insulin in Atrophic Acne Scarring: A Systematic Review of Efficacy, Safety, and Patient Satisfaction
Background: Atrophic acne scars are challenging to treat and have a negative psychological impact. Insulin has been tried as a topical adjuvant and stimulates fibroblast activity, collagen deposition, and keratinocyte migration. Objectives: To evaluate topical insulin for atrophic acne scars in terms of its effectiveness, safety, and patient-rated results. Methods: Five databases were searched for research on topical insulin, either alone or in conjunction with a procedure, without regard to the date. Records were screened, extracted, and evaluated in duplicate (RoB 2 or ROBINS-I) each by two independent researchers, using Covidence. Results: Fourteen studies with 619 patients, seven randomized and seven non-randomized, were qualified. All insulin arms improved from baseline (35.8% to 55.4%), but comparator arms mostly improved similarly; five studies, none at low risk of bias, favored insulin. Adverse effects were mostly local, minor, and transient, although one study reported systemic hypoglycemia-related symptoms; glucose monitoring was inconsistent, and satisfaction was high. Limitations: Meta-analysis was not possible due to heterogeneity in design, dosage, and outcome scales, and the small number of patients precludes certain conclusions. Conclusions: Although its superiority over current adjuncts has not been demonstrated, topical insulin appears to be an affordable, well-tolerated adjunct that may have a function where traditional therapies are unavailable; larger studies are needed.
Open AccessTopical Insulin in Atrophic Acne Scarring: A Systematic Review of Efficacy, Safety, and Patient Satisfaction
Background: Atrophic acne scars are challenging to treat and have a negative psychological impact. Insulin has been tried as a topical adjuvant and stimulates fibroblast activity, collagen deposition, and keratinocyte migration. Objectives: To evaluate topical insulin for atrophic acne scars in terms of its effectiveness, safety, and patient-rated results. Methods: Five databases were searched for research on topical insulin, either alone or in conjunction with a procedure, without regard to the date. Records were screened, extracted, and evaluated in duplicate (RoB 2 or ROBINS-I) each by two independent researchers, using Covidence. Results: Fourteen studies with 619 patients, seven randomized and seven non-randomized, were qualified. All insulin arms improved from baseline (35.8% to 55.4%), but comparator arms mostly improved similarly; five studies, none at low risk of bias, favored insulin. Adverse effects were mostly local, minor, and transient, although one study reported systemic hypoglycemia-related symptoms; glucose monitoring was inconsistent, and satisfaction was high. Limitations: Meta-analysis was not possible due to heterogeneity in design, dosage, and outcome scales, and the small number of patients precludes certain conclusions. Conclusions: Although its superiority over current adjuncts has not been demonstrated, topical insulin appears to be an affordable, well-tolerated adjunct that may have a function where traditional therapies are unavailable; larger studies are needed.
- Open Access
- 20 September 2023
- Published by Wiley in JEADV Clinical Practice
- Vol. 3 (1) , 239-241
Burden of treatment in severe acne vulgaris
Background: Acne is associated with a significant burden of disease related to the visual impact of facial lesions, symptoms such as pain, and sequelae such as scarring. However, little research has been performed on the acne‐specific burden of treatment (BOT), defined as the workload of healthcare as well as its impact on functioning and well‐being.Objectives: The aim of this study was to examine the BOT of moderate‐severe acne.Methods: A prospective study was performed in our tertiary dermatology department. Patients attending the dermatology department with moderate‐severe acne (defined as an Investigator's Global Assessment of acne severity of 3 or 4) were invited to complete a validated BOT questionnaire, modified for use in acne, with additional qualitative components.Results: Of 50 patients, 68% were female, with a mean age of 22.6 years (range 16‐45 years). Most (82%, n = 41) patients were on isotretinoin, with 18% (n = 9) on oral antibiotics. The average BOT was 4.2/10 (range 0–8.2) for topical therapies, 4.5/10 (range 2.7–6.8) for oral antibiotics, and 3.8/10 (range 0.69–6.9) for isotretinoin. From qualitative statements, the greatest burdens reported with topical treatment were unpleasant sensations, skin sensitivity, skin dryness, and lack of efficacy; with antibiotic therapy were the requirement for long‐term treatment, limited efficacy, and side‐effects including gastrointestinal upset; and with isotretinoin therapy were cheilitis and xerosis, cost, and need for blood tests. However, 58% (n = 29) of patients believed their overall BOT was decreased with isotretinoin, and 18% (n = 9) felt that it was unchanged with isotretinoin, with statements such as “the side effects can be tough, but the result is definitely worth it.”Conclusions: The BOT associated with oral isotretinoin is similar or lower to topical therapies and oral antibiotics. This should be taken into consideration when optimizing the care of patients with acne.
- 20 September 2023
- Published by Wiley in JEADV Clinical Practice
- Vol. 3 (1) , 239-241
Open AccessBurden of treatment in severe acne vulgaris
Background: Acne is associated with a significant burden of disease related to the visual impact of facial lesions, symptoms such as pain, and sequelae such as scarring. However, little research has been performed on the acne‐specific burden of treatment (BOT), defined as the workload of healthcare as well as its impact on functioning and well‐being.Objectives: The aim of this study was to examine the BOT of moderate‐severe acne.Methods: A prospective study was performed in our tertiary dermatology department. Patients attending the dermatology department with moderate‐severe acne (defined as an Investigator's Global Assessment of acne severity of 3 or 4) were invited to complete a validated BOT questionnaire, modified for use in acne, with additional qualitative components.Results: Of 50 patients, 68% were female, with a mean age of 22.6 years (range 16‐45 years). Most (82%, n = 41) patients were on isotretinoin, with 18% (n = 9) on oral antibiotics. The average BOT was 4.2/10 (range 0–8.2) for topical therapies, 4.5/10 (range 2.7–6.8) for oral antibiotics, and 3.8/10 (range 0.69–6.9) for isotretinoin. From qualitative statements, the greatest burdens reported with topical treatment were unpleasant sensations, skin sensitivity, skin dryness, and lack of efficacy; with antibiotic therapy were the requirement for long‐term treatment, limited efficacy, and side‐effects including gastrointestinal upset; and with isotretinoin therapy were cheilitis and xerosis, cost, and need for blood tests. However, 58% (n = 29) of patients believed their overall BOT was decreased with isotretinoin, and 18% (n = 9) felt that it was unchanged with isotretinoin, with statements such as “the side effects can be tough, but the result is definitely worth it.”Conclusions: The BOT associated with oral isotretinoin is similar or lower to topical therapies and oral antibiotics. This should be taken into consideration when optimizing the care of patients with acne.
- Open Access
- 16 May 2022
- Published by Oxford University Press (OUP) in Skin Health and Disease
- Vol. 2 (3) , e125
Burden of Treatment in Vulval Lichen Sclerosus
Lichen sclerosus (LS) is a chronic inflammatory dermatosis predominantly affecting the anogenital region, which can have significant impact on quality of life. Burden of treatment (BOT) is defined as the workload of healthcare experienced by patients and consequences on well-being. In this prospective study, 35 women with vulval LS completed a detailed Treatment Burden Questionnaire to assess their BOT. Nineteen (54.3%) achieved a score of 35 or less, signifying low BOT; ten (28.6%) between 36 and 65, signifying moderate BOT; and six (17.1%) above 65, signifying high BOT. Seven (20%) patients reported BOT scores of greater than 59, which has been designated as a cut-off for increased risk of treatment-related burnout. Higher BOT scores were moderately correlated with higher DLQI scores (r = 0.47, p < 0.01). BOT in LS is low for most patients, although a minority are at risk of treatment-related burnout. BOT should be considered when forming treatment guidelines for LS.
- 16 May 2022
- Published by Oxford University Press (OUP) in Skin Health and Disease
- Vol. 2 (3) , e125
Open AccessBurden of Treatment in Vulval Lichen Sclerosus
Lichen sclerosus (LS) is a chronic inflammatory dermatosis predominantly affecting the anogenital region, which can have significant impact on quality of life. Burden of treatment (BOT) is defined as the workload of healthcare experienced by patients and consequences on well-being. In this prospective study, 35 women with vulval LS completed a detailed Treatment Burden Questionnaire to assess their BOT. Nineteen (54.3%) achieved a score of 35 or less, signifying low BOT; ten (28.6%) between 36 and 65, signifying moderate BOT; and six (17.1%) above 65, signifying high BOT. Seven (20%) patients reported BOT scores of greater than 59, which has been designated as a cut-off for increased risk of treatment-related burnout. Higher BOT scores were moderately correlated with higher DLQI scores (r = 0.47, p < 0.01). BOT in LS is low for most patients, although a minority are at risk of treatment-related burnout. BOT should be considered when forming treatment guidelines for LS.